Dennis C. Copertino

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

Jesper Damsgaard Gunst, Marie H. Pahus, Míriam Rosás-Umbert et al. · Nature Medicine · 2022 · 140 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity

Míriam Rosás-Umbert, Jesper Damsgaard Gunst, Marie H. Pahus et al. · Nature Communications · 2022 · 97 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

Jesper Damsgaard Gunst, Jesper Falkesgaard Højen, Marie H. Pahus et al. · Nature Medicine · 2023 · 83 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab

Sonia Elhadad, John Chapin, Dennis C. Copertino et al. · Clinical & Experimental Immunology · 2020 · 56 citations · Full text

Life Sciences, Hematology, Pathology +16

SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells

Eva M. Stevenson, Sandra Terry, Dennis C. Copertino et al. · Nature Communications · 2022 · 35 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17